FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307967327> ?p ?o ?g. }

• W4307967327 endingPage "487" @default.
• W4307967327 startingPage "472" @default.
• W4307967327 abstract "Abstract Purpose: PAX-fusion negative rhabdomyosarcoma (FN RMS) is driven by alterations in the RAS/MAP kinase pathway and is partially responsive to MEK inhibition. Overexpression of IGF1R and its ligands is also observed in FN RMS. Preclinical and clinical studies have suggested that IGF1R is itself an important target in FN RMS. Our previous studies revealed preclinical efficacy of the MEK1/2 inhibitor, trametinib, and an IGF1R inhibitor, BMS-754807, but this combination was not pursued clinically due to intolerability in preclinical murine models. Here, we sought to identify a combination of an MEK1/2 inhibitor and IGF1R inhibitor, which would be tolerated in murine models and effective in both cell line and patient-derived xenograft models of RAS-mutant FN RMS. Experimental Design: Using proliferation and apoptosis assays, we studied the factorial effects of trametinib and ganitumab (AMG 479), a mAb with specificity for human and murine IGF1R, in a panel of RAS-mutant FN RMS cell lines. The molecular mechanism of the observed synergy was determined using conventional and capillary immunoassays. The efficacy and tolerability of trametinib/ganitumab was assessed using a panel of RAS-mutated cell-line and patient-derived RMS xenograft models. Results: Treatment with trametinib and ganitumab resulted in synergistic cellular growth inhibition in all cell lines tested and inhibition of tumor growth in four of six models of RAS-mutant RMS. The combination had little effect on body weight and did not produce thrombocytopenia, neutropenia, or hyperinsulinemia in tumor-bearing SCID beige mice. Mechanistically, ganitumab treatment prevented the phosphorylation of AKT induced by MEK inhibition alone. Therapeutic response to the combination was observed in models without a mutation in the PI3K/PTEN axis. Conclusions: We demonstrate that combined trametinib and ganitumab is effective in a genomically diverse panel of RAS-mutated FN RMS preclinical models. Our data also show that the trametinib/ganitumab combination likely has a favorable tolerability profile. These data support testing this combination in a phase I/II clinical trial for pediatric patients with relapsed or refractory RAS-mutated FN RMS." @default.
• W4307967327 created "2022-11-06" @default.
• W4307967327 creator A5003760804 @default.
• W4307967327 creator A5008512054 @default.
• W4307967327 creator A5016125176 @default.
• W4307967327 creator A5017446252 @default.
• W4307967327 creator A5017638182 @default.
• W4307967327 creator A5021815921 @default.
• W4307967327 creator A5023309436 @default.
• W4307967327 creator A5025441472 @default.
• W4307967327 creator A5026472811 @default.
• W4307967327 creator A5027588227 @default.
• W4307967327 creator A5027603271 @default.
• W4307967327 creator A5034122767 @default.
• W4307967327 creator A5039558062 @default.
• W4307967327 creator A5046749793 @default.
• W4307967327 creator A5049469240 @default.
• W4307967327 creator A5051052453 @default.
• W4307967327 creator A5051562975 @default.
• W4307967327 creator A5052710405 @default.
• W4307967327 creator A5055187581 @default.
• W4307967327 creator A5060984679 @default.
• W4307967327 creator A5063126623 @default.
• W4307967327 creator A5063240531 @default.
• W4307967327 creator A5063835774 @default.
• W4307967327 creator A5067560793 @default.
• W4307967327 creator A5068834354 @default.
• W4307967327 creator A5073986134 @default.
• W4307967327 creator A5074840214 @default.
• W4307967327 creator A5078109792 @default.
• W4307967327 creator A5079418869 @default.
• W4307967327 creator A5079644293 @default.
• W4307967327 creator A5084242965 @default.
• W4307967327 creator A5088970778 @default.
• W4307967327 creator A5089594291 @default.
• W4307967327 creator A5090223620 @default.
• W4307967327 date "2022-11-02" @default.
• W4307967327 modified "2023-10-02" @default.
• W4307967327 title "The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models" @default.
• W4307967327 cites W1503731208 @default.
• W4307967327 cites W1545612850 @default.
• W4307967327 cites W1734521060 @default.
• W4307967327 cites W1763480351 @default.
• W4307967327 cites W1905490737 @default.
• W4307967327 cites W19745091 @default.
• W4307967327 cites W1991628301 @default.
• W4307967327 cites W1999455768 @default.
• W4307967327 cites W2014166552 @default.
• W4307967327 cites W2024345327 @default.
• W4307967327 cites W2028199817 @default.
• W4307967327 cites W2045773193 @default.
• W4307967327 cites W2050206485 @default.
• W4307967327 cites W2062972691 @default.
• W4307967327 cites W2069872642 @default.
• W4307967327 cites W2079547534 @default.
• W4307967327 cites W2085749661 @default.
• W4307967327 cites W2100034382 @default.
• W4307967327 cites W2100614336 @default.
• W4307967327 cites W2106321700 @default.
• W4307967327 cites W2113309935 @default.
• W4307967327 cites W2122349489 @default.
• W4307967327 cites W2127736279 @default.
• W4307967327 cites W2128086717 @default.
• W4307967327 cites W2144991904 @default.
• W4307967327 cites W2154321500 @default.
• W4307967327 cites W2156768359 @default.
• W4307967327 cites W2164729625 @default.
• W4307967327 cites W2165575701 @default.
• W4307967327 cites W2167156722 @default.
• W4307967327 cites W2167334545 @default.
• W4307967327 cites W2169546036 @default.
• W4307967327 cites W2289200327 @default.
• W4307967327 cites W2346079527 @default.
• W4307967327 cites W2550469381 @default.
• W4307967327 cites W2704415527 @default.
• W4307967327 cites W2750663875 @default.
• W4307967327 cites W2754809261 @default.
• W4307967327 cites W2803222616 @default.
• W4307967327 cites W2804804971 @default.
• W4307967327 cites W2811415290 @default.
• W4307967327 cites W2887730046 @default.
• W4307967327 cites W2891277144 @default.
• W4307967327 cites W2917986762 @default.
• W4307967327 cites W2947368578 @default.
• W4307967327 cites W2953238030 @default.
• W4307967327 cites W2983859438 @default.
• W4307967327 cites W2991430679 @default.
• W4307967327 cites W2995031569 @default.
• W4307967327 cites W3077914340 @default.
• W4307967327 cites W3095387000 @default.
• W4307967327 cites W3110475662 @default.
• W4307967327 cites W3175499653 @default.
• W4307967327 cites W3183139760 @default.
• W4307967327 cites W3201244242 @default.
• W4307967327 cites W3214496898 @default.
• W4307967327 cites W4226207639 @default.
• W4307967327 cites W4239499995 @default.
• W4307967327 cites W848101669 @default.

• next